Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biondvax Pharma ADR (NQ: BVXV )

2.170 -0.050 (-2.25%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,021
Open 2.190
Bid (Size) 2.170 (1)
Ask (Size) 2.250 (2)
Prev. Close 2.220
Today's Range 2.170 - 2.210
52wk Range 2.033 - 22.90
Shares Outstanding 461,285,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
Via Investor Brand Network
Exposures COVID-19
New Approach Could Boost Current Asthma Medication Efficacy
Via Investor Brand Network

Performance

YTD
-27.88%
-27.88%
1 Month
-6.47%
-6.47%
3 Month
-32.76%
-32.76%
6 Month
-79.72%
-79.72%
1 Year
-84.16%
-84.16%

More News

Read More
Japan to Categorize COVID-19 as Common Infectious Illness
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring
Via Investor Brand Network
Exposures COVID-19
Risk Factors of Age-Related Macular Degeneration
Via Investor Brand Network
BiondVax to Present at BIO-Europe Spring
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
Study Shows Air Pollution in Urban Areas Worsens Lung Function in Kids
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders
Via Investor Brand Network
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Climate Change Heightening Risk of Global Infectious Illnesses
Via Investor Brand Network
Topics Climate Change
Exposures COVID-19 Climate
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), Collaborators Positioned to Rapidly Develop Neutralizing NanoAbs for Emerging COVID-19 Variants
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants
Via Investor Brand Network
Exposures COVID-19 Product Safety
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages
Via Investor Brand Network
Exposures COVID-19
Study Finds Common Fatty Acid May Increase Pain, Temperature Sensitivity in Psoriasis
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth
Via Investor Brand Network
New Model Sheds Light on Patterns of Infectious Illnesses
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
Via Investor Brand Network
Exposures COVID-19 Product Safety
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference
Via Investor Brand Network
Exposures COVID-19
BiondVax Presenting at BIO CEO & Investor Conference
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
Research Links Two Natural Deposits to Onset of Macular Degeneration
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.